Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8088769rdf:typepubmed:Citationlld:pubmed
pubmed-article:8088769lifeskim:mentionsumls-concept:C0206694lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0948750lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C1522472lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0596290lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0030415lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C1537692lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C1705191lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C1552923lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C1552858lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C1551341lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C1552924lld:lifeskim
pubmed-article:8088769lifeskim:mentionsumls-concept:C0205155lld:lifeskim
pubmed-article:8088769pubmed:issue9lld:pubmed
pubmed-article:8088769pubmed:dateCreated1994-10-18lld:pubmed
pubmed-article:8088769pubmed:abstractTextMucoepidermoid carcinomas of salivary gland origin have an uncertain clinical course not directly predictable by histomorphology. The MIB 1 antibody, which detects Ki-67 antigen in formalin-fixed, paraffin-embedded tissues, was used to study cell proliferation in these tumors. An MIB 1 index was developed to express the percentage of MIB 1-positive proliferating cells, and the results were compared with histomorphological tumor grade and clinical outcome. All patients with MIB 1 indices lower than 10% in their primary tumors had a favorable clinical outcome. Most patients with MIB 1 indices higher than 10% developed a recurrent or metastasizing disease. All patients who died of their tumor or who had persistent tumor had MIB 1 indices higher than 10%. Thus, the MIB 1 index defines two virtually nonoverlapping forms of the disease, an indolent one and an aggressive one. Cell proliferation in mucoepidermoid carcinomas, assessed with the MIB 1 antibody, thus represents a significant prognostic factor for improving the accuracy of conventional histological grading.lld:pubmed
pubmed-article:8088769pubmed:languageenglld:pubmed
pubmed-article:8088769pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8088769pubmed:citationSubsetIMlld:pubmed
pubmed-article:8088769pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8088769pubmed:statusMEDLINElld:pubmed
pubmed-article:8088769pubmed:monthSeplld:pubmed
pubmed-article:8088769pubmed:issn0046-8177lld:pubmed
pubmed-article:8088769pubmed:authorpubmed-author:LeivoIIlld:pubmed
pubmed-article:8088769pubmed:authorpubmed-author:SkalovaAAlld:pubmed
pubmed-article:8088769pubmed:authorpubmed-author:LehtonenHHlld:pubmed
pubmed-article:8088769pubmed:authorpubmed-author:von...lld:pubmed
pubmed-article:8088769pubmed:issnTypePrintlld:pubmed
pubmed-article:8088769pubmed:volume25lld:pubmed
pubmed-article:8088769pubmed:ownerNLMlld:pubmed
pubmed-article:8088769pubmed:authorsCompleteYlld:pubmed
pubmed-article:8088769pubmed:pagination929-35lld:pubmed
pubmed-article:8088769pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:meshHeadingpubmed-meshheading:8088769-...lld:pubmed
pubmed-article:8088769pubmed:year1994lld:pubmed
pubmed-article:8088769pubmed:articleTitlePrognostic significance of cell proliferation in mucoepidermoid carcinomas of the salivary gland: clinicopathological study using MIB 1 antibody in paraffin sections.lld:pubmed
pubmed-article:8088769pubmed:affiliationDepartment of Pathology, University of Helsinki, Finland.lld:pubmed
pubmed-article:8088769pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8088769pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8088769lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8088769lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8088769lld:pubmed